AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

AstraZeneca and Amgen Announced Results for Tezepelumab for Severe Asthma

  • Tezepelumab Reduced Exacerbations by 77% in Subgroup of Patients with Elevated Inflammatory Biomarkers in NAVIGATOR 
  • Tezepelumab Reduced Exacerbations Requiring Hospitalization by 85%

AstraZeneca (AZN) and Amgen (This content is for paid subscribers.

Please click here to subscribe or here to log in.